2013年ASCO会议关于转移性结直肠癌靶向治疗的热点问题

Hot spots about target therapy of metastasis colorectal cancer on the 2013 ASCO conference

2013年ASCO会议发表了3项结直肠癌的重要临床研究,内容涉及目前转移性结直肠癌临床研究的热点问题,包括靶向药物治疗策略的优化、最佳的维持治疗模式、疗效预测等。其中FIRE3研究未能对KRAS野生型转移性结直肠癌一线治疗西妥昔单抗和贝伐珠单抗孰优孰劣这一问题得出明确的结论。CARIO3研究支持贝伐珠单抗联合卡培他滨作为结直肠癌化疗维持治疗的新模式。PRIME研究的后续数据以及其他临床研究结果表明,除KRAS之外,NRAS,BRAF和PIK3CA基因突变也是EGFR单抗疗效的负预测因子。

On the 2013 ASCO conference,there were three important clinical study results released in which involved the hot spots of metastasis colorectal cancer,such as optimization of targeted drug therapy,the best mode of treatment and curative effect prediction.The FIRE3 study failed to make a clear conclusion on the comparison of the first-line drug cetuximab and bevacizumab in the treatment of the wild type KRAS metastatic colorectal cancer.CARIO3 research supported bevacizumab plus capecitabine as a new mode of chemotherapy for colorectal cancer.The follow-up data from the PRIME study and other clinical research results showed that NRAS,BRAF and PIK3CA gene mutation might be a negative predictors of the EGFR monoclonal antibody effectiveness,except KRAS.